PMID- 34237387
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1873-6963 (Electronic)
IS  - 0965-2299 (Linking)
VI  - 60
DP  - 2021 Aug
TI  - Effects of chromium supplementation on blood pressure, body mass index, liver 
      function enzymes and malondialdehyde in patients with type 2 diabetes: A 
      systematic review and dose-response meta-analysis of randomized controlled 
      trials.
PG  - 102755
LID - S0965-2299(21)00096-0 [pii]
LID - 10.1016/j.ctim.2021.102755 [doi]
AB  - BACKGROUND: Several studies reported beneficial effects of chromium 
      supplementation for management of type 2 diabetes mellitus (T2DM). The present 
      study aimed to provide a systematic review and meta-analysis of randomized 
      controlled trials (RCTs) examining the effects of chromium supplementation on 
      blood pressure, body mass index (BMI), liver function enzymes and malondialdehyde 
      (MDA) in patients with T2DM. METHODS: PubMed, Scopus, and Embase were searched up 
      to 15 November 2020 with no language and time restriction. RCTs that reported the 
      effects of chromium supplementation on blood pressure, BMI, liver function 
      enzymes and MDA in patients with T2DM were included. A random-effects model was 
      used to compute weighted mean differences (WMDs) with 95 % confidence intervals 
      (CIs). Between-study heterogeneity was assessed by Cochran's Q test and 
      quantified by I(2) statistic. RESULTS: Of 3586 publications, 15 RCTs were 
      included for the meta-analysis. Pooled effect sizes indicated that chromium 
      significantly reduced diastolic blood pressure (DBP) (WMD): -2.36 mmHg, 95 % CI: 
      -4.14, -0.60; P = 0.008), and MDA (WMD: -0.55 umol/l, 95 % CI: -0.96, -0.14; P = 
      0.008). However, chromium supplementation did not significantly affect BMI, 
      systolic blood pressure (SBP), alanine aminotransferase (ALT), aspartate 
      aminotransferase (AST). Meta-regression analysis did not show significant linear 
      relationship between dose of chromium and change in BMI (p = 0.412), SBP (p = 0. 
      319), DBP (p = 0.102), ALT (p = 0.923), AST (p = 0.986) and MDA (p = 0.055). 
      CONCLUSION: The present systematic review and meta-analysis shows that 
      supplementation with chromium at dose of 200-1000 mug/day may reduce DBP and MDA 
      in T2DM patients.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Asbaghi, Omid
AU  - Asbaghi O
AD  - Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran. Electronic address: omid.asbaghi@gmail.com.
FAU - Naeini, Fatemeh
AU  - Naeini F
AD  - Department of Clinical Nutrition, School of Nutritional Science, Tehran 
      University of Medical Science, Tehran, Iran. Electronic address: 
      DR.fnaeeni@gmail.com.
FAU - Ashtary-Larky, Damoon
AU  - Ashtary-Larky D
AD  - Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of 
      Medical Sciences, Ahvaz, Iran. Electronic address: Damoon_ashtary@yahoo.com.
FAU - Kaviani, Mojtaba
AU  - Kaviani M
AD  - Faculty of Pure & Applied Science, School of Nutrition and Dietetics, Acadia 
      University, Wolfville, NS, Canada. Electronic address: 
      Mojtaba.kaviani@acadiau.ca.
FAU - Rezaei Kelishadi, Mahnaz
AU  - Rezaei Kelishadi M
AD  - Department of Community Nutrition, School of Nutrition and Food Science, Isfahan 
      University of Medical Sciences, Isfahan, Iran. Electronic address: 
      m.rezaei81@yahoo.com.
FAU - Eslampour, Elham
AU  - Eslampour E
AD  - Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, 
      Iran. Electronic address: islampoor.eli@gmail.com.
FAU - Moradi, Sajjad
AU  - Moradi S
AD  - Department of Community Nutrition, School of Nutrition and Food Science, Isfahan 
      University of Medical Sciences, Isfahan, Iran. Electronic address: 
      sajadmoradi9096@gmail.com.
FAU - Mirzadeh, Elahe
AU  - Mirzadeh E
AD  - Department of Physical Education and Sports Science, Central Tehran Branch, 
      Islamic Azad University, Tehran, Iran.
FAU - Clark, Cain C T
AU  - Clark CCT
AD  - Centre for Intelligent Healthcare, Coventry University, Coventry, CV1 5FB, UK. 
      Electronic address: ad0183@coventry.ac.uk.
FAU - Naeini, Amirmansour Alavi
AU  - Naeini AA
AD  - Department of Community Nutrition, School of Nutrition and Food Science, Isfahan 
      University of Medical Sciences, Isfahan, Iran. Electronic address: 
      am.alavi@nutr.mui.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20210705
PL  - Scotland
TA  - Complement Ther Med
JT  - Complementary therapies in medicine
JID - 9308777
RN  - 0R0008Q3JB (Chromium)
RN  - 4Y8F71G49Q (Malondialdehyde)
SB  - IM
MH  - Blood Pressure
MH  - Body Mass Index
MH  - *Chromium
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Dietary Supplements
MH  - Humans
MH  - Liver
MH  - Malondialdehyde
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Blood pressure
OT  - Body mass index
OT  - Chromium
OT  - Liver function enzymes
OT  - Malondialdehyde
OT  - Type 2 diabetes
EDAT- 2021/07/09 06:00
MHDA- 2021/11/25 06:00
CRDT- 2021/07/08 20:13
PHST- 2020/10/15 00:00 [received]
PHST- 2021/05/10 00:00 [revised]
PHST- 2021/06/21 00:00 [accepted]
PHST- 2021/07/09 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2021/07/08 20:13 [entrez]
AID - S0965-2299(21)00096-0 [pii]
AID - 10.1016/j.ctim.2021.102755 [doi]
PST - ppublish
SO  - Complement Ther Med. 2021 Aug;60:102755. doi: 10.1016/j.ctim.2021.102755. Epub 
      2021 Jul 5.